EAN NewsNews in general

EAN joint session at 37th ECTRIMS Congress to focus on vaccination and treatment guidelines for people with multiple sclerosis

September 13, 2021

by Prof. Massimo Filippi

The annual congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) offers a great opportunity for all researchers, clinicians and people with multiple sclerosis (MS) to meet each other and get up to date with the most recent and relevant advances in knowledge in different fields of MS.

This year, at the upcoming 37th ECTRIMS congress, the ECTRIMS-EAN Session, chaired by Profs. Massimo Filippi, Mar Tintoré, Maria Pia Amato and Celia Oreja-Guevara, will discuss two key aspects of MS management: the consensus regarding vaccinations in people with MS and the updated guidelines for MS treatment.

People with MS are often at increased risk of infections compared to the general population due to their clinical disability, the presence of comorbidities and the use of therapies that suppress or modulate their immune systems. Accordingly, to prevent some severe infections and their complications, people with MS should be vaccinated. However, several concerns, increased following the recent COVID-19 pandemic, have been raised regarding the efficacy and the safety of vaccinations in these patients.

In the first section of the ECTRIMS-EAN Session, Prof. Sandra Vukusic will discuss current evidence of safety and immunogenicity of vaccinations in people with MS. Then, Dr. Susana Otero-Romero will describe the recommended standards and protocols for vaccinations in these patients. Finally, Dr. Mauricio Farez will summarise the current position regarding COVID-19 vaccinations.

During the last few years, the therapeutic scenario for MS has undergone a dramatic evolution. This has been made possible thanks to the introduction of more and more effective treatments and the demonstration that these drugs, especially if started early, can substantially impact the prognosis of people with MS. Beside this, an accurate definition of treatment responders and a careful monitoring of treatment-related adverse effects are very much necessary.

These aspects will be the topic of the second section of the ECTRIMS-EAN Session. First, Dr. Simón Cárdenas-Robledo will provide a methodological overview regarding how guidelines can be developed and finalised. Then, Prof. Xavier Montalban will wisely summarise the 2021 update of the ECTRIMS/EAN Clinical Guidelines on the treatment of people with MS. These will represent a milestone for management of MS in the upcoming years.

We will be happy to see you there and I hope a great number of participants will attend this very important session on Friday, October 15, 2021, at 15:00-16:30h CEST.

You may also like

Symposium 3 – Myasthenia gravis: What is our current knowledge on diagnostics and therapy?

June 27, 2022
Dear EAN members, dear friends, It is my pleasure to give you an update on behalf of the EAN Scientific Committee following a busy year since my appointment as chair. It has been a privilege to be so deeply involved in the scientific activities of the EAN and to work closely with an amazing community of people who are so dedicated to the advancement of neurology. One of the strongest threads within that community is the EAN’s group of Scientific Panels, which are often referred to as the organisation’s ‘scientific backbone’. The panels have a hand in everything the EAN does from a scientific point of view, including coordinating clinical research, disseminating good practice, assisting in planning the EAN annual congress, supporting the EAN’s educational efforts, and producing guidelines that assist neurologists in daily practice. All of this work requires a considerable amount of oversight, and this is why each panel is run by its own Management Group, elected by the panel members. Being a part of one of these Management Groups (PDF) is an opportunity to play a direct part in determining the direction of scientific progress within Europe, and I am excited to say that the call for applications to stand for election will be announced in September. All panel members and EAN individual members are eligible to apply to be candidates, with the vote being held among the existing panel members in autumn. I would like to urge every neurologist with a passion for the scientific future of their special area of interest to consider standing for election to the relevant Management Group and to look out for the call for applications later this month. I can tell you from personal experience that fulfilling a role such as this within the structure of the EAN is a fascinating and extremely rewarding experience. The chance to take on such a unique leadership position should not be missed! The most satisfying aspect of being involved in the EAN’s organisational structure is surely seeing all the hard work and planning come to fruition when a small idea evolves into a newly launched project. One such example is the 1st EAN Science School, taking place in Salzburg next March. The idea of the Science School is to offer early career neurologists with an interest in translational research a new avenue for learning about basic pathomechanisms of neurological disorders. Application for this very first edition, on ‘Pathophysiology of disorders of the nervous system’, closed last week and we have been delighted with the level of interest. It was a pleasure to be part of the task force in charge of planning this new project and I look forward to seeing it officially transferred to the hands of the Scientific Committee after a successful event and evaluation in spring. Of our ongoing activities, one of the most significant is the EAN Neuro-covid Registry, which aims to collate epidemiological data on neurological manifestations in patients with COVID-19 infection reported by neurologists in outpatient services, emergency rooms, and hospital departments. We currently have 1,542 patients entered in the database, from 35 centres across 23 countries. So far, 29 patients have been followed for 12 months and 387 have completed the 6-months follow up. This is a decent start, but I would like to strongly encourage EAN members and their institutions to get involved and contribute cases to what will become an invaluable resource for neurologists and clinicians to improve care for Covid-19 patients. Finally, I would like share a word on a forthcoming collaboration between EAN and the Human Brain Project in December, that I think will interest a lot of EAN members. The EAN-EBRAINS joint workshop on ‘The future of medical data sharing in clinical neurosciences’ will be a three-day virtual event that aims to discuss issues and challenges associated with data sharing in Europe, from ethics to data safety and privacy, including those specific to data federation, such as the development and validation of federated algorithms. The whole workshop is completely free of charge and registration is open until 25 November, so please check out the details and sign up! I wish you all a healthy and pleasant autumn and I look forward to updating you again. Best wishes Thomas Berger Chair of the EAN Scientific Committee

Executive Page: New guideline prioritisation process begins setting path for next two years

November 1, 2022

Research Paper of the Month: Association of intraventricular fibrinolysis with clinical outcomes in ICH: an individual participant data meta-analysis

July 8, 2022

EAN Day to take place in Almaty Kazakhstan April 18

February 28, 2020

EAN endorsed meetings in May 2019

May 1, 2019

Launch of European Dystonia Research Consortium: EurDyscover

October 1, 2020

The EAN Congress Quiz

January 12, 2016

See What’s New in the European Journal of Neurology

January 7, 2015

EAN 2021 Must-See Sessions: Tuesday, 22 June

June 21, 2021

New EAN Regional Teaching initiative – host an EAN session at your national society’s meeting

March 30, 2023